Volume 17, Number 7—July 2011
Tickborne Relapsing Fever Caused by Borrelia persica, Uzbekistan and Tajikistan
Highlight and copy the desired format.
|EID||Colin de Verdière N, Hamane S, Assous M, Sertour N, Ferquel E, Cornet M, et al. Tickborne Relapsing Fever Caused by Borrelia persica, Uzbekistan and Tajikistan. Emerg Infect Dis. 2011;17(7):1325-1327. https://dx.doi.org/10.3201/eid1707.101894|
|AMA||Colin de Verdière N, Hamane S, Assous M, et al. Tickborne Relapsing Fever Caused by Borrelia persica, Uzbekistan and Tajikistan. Emerging Infectious Diseases. 2011;17(7):1325-1327. doi:10.3201/eid1707.101894.|
|APA||Colin de Verdière, N., Hamane, S., Assous, M., Sertour, N., Ferquel, E., & Cornet, M. (2011). Tickborne Relapsing Fever Caused by Borrelia persica, Uzbekistan and Tajikistan. Emerging Infectious Diseases, 17(7), 1325-1327. https://dx.doi.org/10.3201/eid1707.101894.|
To the Editor: Tickborne relapsing fever (TBRF) is caused by several Borrelia species and transmitted by argasid soft ticks of the genus Ornithodoros. The disease is endemic to many parts of the world, especially Africa (B. duttonii and B. crocidurae most prevalent), and the Mediterranean basin (B. hispanica most prevalent). In Eurasia, TBRF is mainly caused by B. persica (1–3). We report a patient who returned to France with B. persica infection after visiting Uzbekistan and Tajikistan.
In September 2008, a 32-year-old man sought care at the Saint Louis Hospital in Paris, France, for a fifth relapsing episode of fever. Three weeks earlier (July 31–August 18), he had trekked through Uzbekistan and Tajikistan and spent 7 nights in a tent in Uzbekistan. The day before his return to France, he had fever (39.5°C) that lasted 5 days without other symptoms. After a 4-day interval, fever recurred for 1 day, then relapsed 3 other times (every 2 days with fever for 12 hours). Laboratory investigations performed earlier by his general physician on August 19 and 20 showed lymphopenia (0.76 × 109 cells/L and 0.44 × 109 cells/L), thrombocytopenia (94 ×109 cells/L and 80 ×109 cells/L), and C-reactive protein level 300 mg/L (reference level <6 mg/L).
Physical examination when the man was afebrile found no clinical abnormalities. He did not recall tick bites, and no lesion was seen on his skin. Laboratory investigations on September 2 indicated persistant lymphopenia (1.0 × 109 cells/L), C-reactive protein 96 mg/L, and mild cholestasis (alkaline phosphatase level 125 UI/L and gamma glutamyl transferase level 92 UI/L). Thick and thin Giemsa-stained blood smears showed neither Plasmodium spp. nor Borrelia spp. However, quantitative buffy coat analysis (QBC; Becton Dickinson, Le Pont de Claix, France) showed numerous spirochetes, which prompted a rereview and careful analysis of the slides, during which spirochetes were infrequently seen. PCR and sequencing of the 16S rRNA gene, performed as previously described, from a whole blood sample identified these bacteria as B. persica (1).
According to current recommendations in France, the patient was given doxycycline, 200 mg/d, for 10 days. During the first 12 hours, he was monitored for a Jarish–Herxheimer reaction, which was not observed. By the end of therapy, inflammatory syndrome and lymphopenia had resolved.
Despite high-level sequence conservation, identification of Borrelia spp. by sequencing the 16S rRNA gene is reliable and useful for clinical practice (1,4–6). The sequence obtained from the patient reported here was identical (100% identity over 1,472 bp) to the B. persica HM161645 reference sequence available from GenBank and sampled from the Galilee region of Israel. It differed by 2 nt (99.86% identity) from B. persica U42297 and another unpublished sequence (B. persica 11/95), each from Iran. B. persica 11/95 was obtained from blood from a rodent collected in Iran and examined at the Institut Pasteur of Iran. We submitted the 2 B. persica sequences (1 from the patient reported here and 1 from the 11/95 sample) to GenBank (accession nos. HQ610930 and HQ610931, respectively). We confirmed identification of B. persica from the patient reported here by sequencing of both flaB and intergenic spacer domains (data not shown), as described (7,8).
Although recently reviewed, the epidemiology of TBRF in the area of the former Union of Soviet Socialist Republics has not been extensively described (3). In most of these countries, the infection is mainly attributed to B. persica and transmitted by Ornithodoros tholozani ticks, which live in caves, soil, wall crevices, houses, and cow sheds. Mammalian reservoirs, if any, are not known (3). However, other agents have been reported, such as B. latyschewii (transmitted by O. tartakovskyi ticks, which inhabit rodent burrows) in Kazakhstan, Uzbekistan, and Turkmenistan and B. caucasica (transmitted by O. verrucosus ticks) in the western shore of the Caspian Sea (Armenia, Azerbaijan, and Georgia) (9,10). Other soft ticks (O. nereensis and O. alactagalis) have been described in central Asia.
To our knowledge, TBRF cases caused by B. persica in Uzbekistan and Tajikistan have been rarely reported. The clinical illness of the patient reported here did not differ substantially from that of patients in Israel, Iran, or Jordan, where the infection is more frequently detected. The illness appears benign without chills, headache, vomiting, arthralgia, epistaxis, or hematuria. However, lymphopenia, which resolved rapidly, has not been described for other TBRF cases.
Our report highlights that TBRF is endemic to countries of the former Union of Soviet Socialist Republics. Physicians should consider this diagnosis for febrile patient returning from this area. Efforts to prevent tick bites should be emphasized. Accurate microbiological diagnosis comprises molecular detection or quantitative buffy coat analyses, each of which enhances sensitivity. However, in most disease-endemic countries, diagnosis is based only on examination of direct blood smears, which can lead to false-negative results and underestimation of the actual extent of this infection (1).
We thank Nuria Marti-Ras for the sequence of the B. persica sample from the Institut Pasteur of Iran (sequence 11/95) and François Rodhain and Guy Baranton for providing information about TBRF epidemiology in the region and reviewing the manuscript.
- Sarih M, Garnier M, Boudebouch N, Bouattour A, Rihani A, Hassar M, Borrelia hispanica relapsing fever, Morocco. Emerg Infect Dis. 2009;15:1626–9.
- Cutler SJ, Abdissa A, Trape JF. New concepts for the old challenge of African relapsing fever borreliosis. Clin Microbiol Infect. 2009;15:400–6.
- Assous MV, Wilamowski A. Relapsing fever borreliosis in Eurasia—forgotten, but certainly not gone! Clin Microbiol Infect. 2009;15:407–14.
- Ras NM, Lascola B, Postic D, Cutler SJ, Rodhain F, Baranton G, Phylogenesis of relapsing fever Borrelia spp. Int J Syst Bacteriol. 1996;46:859–65.
- Scott JC. Typing African relapsing fever spirochetes. Emerg Infect Dis. 2005;11:1722–9.
- Wyplosz B, Mihaila-Amrouche L, Baixench MT, Bigel ML, Berardi-Grassias L, Fontaine C, Imported tickborne relapsing fever, France. Emerg Infect Dis. 2005;11:1801–3.
- Assous MV, Wilamowski A, Bercovier H, Marva E. Molecular characterization of tickborne relapsing fever Borrelia, Israel. Emerg Infect Dis. 2006;12:1740–3.
- Bouattour A, Garnier M, M'Ghirbi Y, Sarih M, Gern L, Ferquel E, Borrelia crocidurae infection of Ornithodoros erraticus (Lucas, 1849) ticks in Tunisia. Vector Borne Zoonotic Dis. 2010;10:825–30.
- Rodhain F. Borrelia et fièvres récurrentes: aspects épidémiologiques actuels. Bull Inst Pasteur. 1976;74:173–218.
- Rasulov I. Ticks status in central Asia with a special emphasis on Uzbekistan. Parasitol Res. 2007;101(Suppl 2):S183–6.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Muriel Cornet, Parasitologie-Mycologie, Institut de Biologie et de Pathologie, CHU de Grenoble, BP 217, 38043 Grenoble Cedex 9, France
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: August 18, 2011
- Page last updated: August 18, 2011
- Page last reviewed: August 18, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)